PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022, New Report Launched

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of Publisher’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Growth within that market will stem from the positive uptake of three therapies: cyclosporine, systemic antihistamines and the Japanese-manufactured topical calcineurin inhibitor, Astellas/Maruho’s Protopic. Collectively, these three therapies will contribute $361.9m sales to the 2022.

Scope

• Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

• Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

• Sales forecast for the top drugs in Japan from 2012-2022.

• Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.

• Understand and capitalize by identifying products that are most likely to ensure a robust return

• Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis

• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

• Make more informed business decisions from insightful and in-depth analysis of drug performance

• Obtain sales forecast for drugs from 2012-2022 in Japan

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-

Spanning over 99 pages, 27 Tables and 4 Figures, “PharmaPoint: Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2022” report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-japan-drug-forecast-and-market-analysis-2022

Browse more Healthcare reports at: http://www.marketresearchreports.com/healthcare